Ranilair 25 Injection contains Ranitidine 25mg, an H2 receptor antagonist widely used to reduce stomach acid and manage gastrointestinal disorders such as GERD, acid reflux, and peptic ulcers. Its precise formulation ensures rapid and reliable relief in hospital and clinical settings.
The injection works by blocking H2 receptors in the stomach lining, decreasing gastric acid secretion, and promoting healing of the gastrointestinal mucosa. It is suitable for patients who require fast-acting, injectable treatment for hyperacidity-related conditions.
For suppliers, Ranilair 25 Injection is a high-demand injectable product with consistent hospital and clinical usage, making it a reliable addition to any gastrointestinal or hospital portfolio. Its therapeutic relevance ensures repeated demand from healthcare providers.
By including Ranilair 25 Injection in your product range, distributors can enhance brand credibility, ensure strong turnover, and access the growing market of gastroenterology injectables, offering an attractive opportunity for business expansion and increased profitability.